Chang Y H
Arthritis Rheum. 1975 Sep-Oct;18(5):493-6. doi: 10.1002/art.1780180511.
Colchicine suppresses the development of carrageenan-induced edema in the rat with a minimum effective oral dose of 6.0 mg/kg. The slope of the dose-response regression line for colchicine differs significantly from that of indomethacin and phenylbutazone. Based on the dosages required to achieve a 50% suppression of this inflammation, colchicine is 0.6 and 1.5 times as potent as indomethacin and phenylbutazone, respectively. In the reversed passive Arthus reaction in the rat, the suppressive activity of colchicine is at least 50 times that of indomethacin and 100 times that of phenylbutazone. The possible significance of these results with regard to the unique effectiveness of colchicine in the treatment of gout is discussed.
秋水仙碱能抑制角叉菜胶诱导的大鼠水肿的发展,口服最小有效剂量为6.0毫克/千克。秋水仙碱剂量-反应回归线的斜率与吲哚美辛和保泰松的斜率有显著差异。根据实现50%炎症抑制所需的剂量,秋水仙碱的效力分别是吲哚美辛的0.6倍和保泰松的1.5倍。在大鼠反向被动Arthus反应中,秋水仙碱的抑制活性至少是吲哚美辛的50倍和保泰松的100倍。讨论了这些结果对于秋水仙碱治疗痛风独特有效性的可能意义。